{"id":502239,"date":"2020-08-14T13:30:01","date_gmt":"2020-08-14T13:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=502239"},"modified":"2020-08-14T13:30:01","modified_gmt":"2020-08-14T13:30:01","slug":"praderwilli-syndrome-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/praderwilli-syndrome-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight_502239.html","title":{"rendered":"Prader-Willi Syndrome Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Prader-Willi Syndrome Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Prader-Willi Syndrome Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>&#8220;Prader-Willi Syndrome &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221;<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight has launched a new report on<strong> &#8220;Prader-Willi Syndrome &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221;.<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s<strong> &#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/prader-willi-syndrome-market\" target=\"_blank\">Prader-Willi Syndrome &#8211; Market Insights, Epidemiology, and Market Forecast-2030<\/a>&#8221;&nbsp;<\/strong>report delivers an in-depth understanding of the Prader-Willi Syndrome, historical and forecasted epidemiology as well as the Prader-Willi Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the facts:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Prader-Willi Syndrome occurs in approximately one out of every 15,000 births.<\/li>\n<li>It affects males and females with equal frequency and affects all races and ethnicities<\/li>\n<li>According to DelveInsight&#8217;s estimation, the total prevalent cases of Prader Willi syndrome (PWS) were found to be ~47,000 for 7 Major Markets in the year 2017<\/li>\n<li>The Prader-Willi Syndrome Association (PWSA) estimates that the prevalence of PWS is approximately 1 in 12-15,000 people in the US. Using the more conservative estimate, this translates into a target population of approximately 22,000 at present which is quite low.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/prader-willi-syndrome-market\">https:\/\/www.delveinsight.com\/sample-request\/prader-willi-syndrome-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of Prader-Willi Syndrome, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies<\/li>\n<li>Comprehensive insight has been provided into the Prader-Willi Syndrome epidemiology and treatment in the 7MM<\/li>\n<li>Additionally, an all-inclusive account of both the current and emerging therapies for Prader-Willi Syndrome are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape<\/li>\n<li>A detailed review of Prader-Willi Syndrome market; historical and forecasted is included in the report, covering drug outreach in the 7MM<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Prader-Willi Syndrome market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/prader-willi-syndrome-market\" target=\"_blank\"><strong>Prader-Willi syndrome<\/strong><\/a> is a complex genetic condition that affects many parts of the body. In infancy, this condition is characterized by weak muscle tone (hypotonia), feeding difficulties, poor growth, and delayed development. Beginning in childhood, affected individuals develop an insatiable appetite, which leads to chronic overeating (hyperphagia) and obesity. Some people with Prader-Willi syndrome, particularly those with obesity, also develop type 2 diabetes (the most common form of diabetes).<\/p>\n<p style=\"text-align: justify;\">The disease occurs due to the loss of function of several genes in a particular region of chromosome number 15. Among these are genes that provide instructions for making molecules called small nucleolar RNAs (snoRNAs).<\/p>\n<p style=\"text-align: justify;\">According to NORD, Prader-Will Syndrome (PWS) is the first syndromic form of neurodevelopmental disorder that was confirmed to be caused due to imprinting errors leading to a genetic multisystem disorder characterized during infancy by lethargy, diminished muscle tone (hypotonia), feeding difficulties, poor weight gain and growth hormone deficiency.<\/p>\n<p style=\"text-align: justify;\">Although considered a &ldquo;rare&rdquo; disorder, PWS is one of the most common conditions seen in genetic clinics and is the most common genetic cause of obesity that has been identified to date.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/prader-willi-syndrome-market\">https:\/\/www.delveinsight.com\/sample-request\/prader-willi-syndrome-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Companies Covered:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Soleno Therapeutics Inc.<\/li>\n<li>Levo Therapeutics<\/li>\n<li>Millendo Therapeutics<\/li>\n<li>Harmony Biosciences<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Drugs Covered:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Diazoxide Choline Controlled-Release (DCCR)<\/li>\n<li>LV-101<\/li>\n<li>Livoletide or AZP-531<\/li>\n<li>Pitolisant<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><strong>Request for free sample:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/prader-willi-syndrome-market\">https:\/\/www.delveinsight.com\/sample-request\/prader-willi-syndrome-market<\/a><\/strong><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Prader-Willi Syndrome<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intelligence Analysis for Prader-Willi Syndrome<\/p>\n<p style=\"text-align: justify;\">4. Prader-Willi Syndrome: Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">4.1. Prader-Willi Syndrome Total Market Share (%) Distribution in 2017<\/p>\n<p style=\"text-align: justify;\">4.2. Prader-Willi Syndrome Total Market Share (%) Distribution in 2030<\/p>\n<p style=\"text-align: justify;\">5. Prader-Willi Syndrome: Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">5.1. Introduction<\/p>\n<p style=\"text-align: justify;\">5.2. Sign and Symptoms&nbsp;<\/p>\n<p style=\"text-align: justify;\">5.3. Pathophysiology&nbsp;<\/p>\n<p style=\"text-align: justify;\">5.4. Risk Factors&nbsp;<\/p>\n<p style=\"text-align: justify;\">5.5. Diagnosis&nbsp;<\/p>\n<p style=\"text-align: justify;\">6. Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Prader-Willi Syndrome Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">7.1. Epidemiology Key Findings<\/p>\n<p style=\"text-align: justify;\">7.2. Assumptions and Rationale: 7MM<\/p>\n<p style=\"text-align: justify;\">7.3. Epidemiology Scenario: 7MM<\/p>\n<p style=\"text-align: justify;\">7.3.1. Prader-Willi Syndrome Epidemiology Scenario in the 7MM (2017-2030)<\/p>\n<p style=\"text-align: justify;\">7.4. United States Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.4.1. Prader-Willi Syndrome Epidemiology Scenario in the United States (2017-2030)<\/p>\n<p style=\"text-align: justify;\">7.5. EU-5 Country-wise Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.5.1. Germany Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.5.1.1. Prader-Willi Syndrome Epidemiology Scenario in Germany (2017-2030)<\/p>\n<p style=\"text-align: justify;\">7.5.2. France Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.5.2.1. Prader-Willi Syndrome Epidemiology Scenario in France (2017-2030)<\/p>\n<p style=\"text-align: justify;\">7.5.3. Italy Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.5.3.1. Prader-Willi Syndrome Epidemiology Scenario in Italy (2017-2030)<\/p>\n<p style=\"text-align: justify;\">7.5.4. Spain Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.5.4.1. Prader-Willi Syndrome Epidemiology Scenario in Spain (2017-2030)<\/p>\n<p style=\"text-align: justify;\">7.5.5. United Kingdom Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.5.5.1. Prader-Willi Syndrome Epidemiology Scenario in the United Kingdom (2017-2030)<\/p>\n<p style=\"text-align: justify;\">7.5.6. Japan Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.5.6.1. Prader-Willi Syndrome Epidemiology Scenario in Japan (2017-2030)<\/p>\n<p style=\"text-align: justify;\">8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">8.1. Prader-Willi Syndrome Treatment and Management<\/p>\n<p style=\"text-align: justify;\">8.2. Prader-Willi Syndrome Treatment Algorithm&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Prader-Willi Syndrome Treatment<\/p>\n<p style=\"text-align: justify;\">11. Marketed Products<\/p>\n<p style=\"text-align: justify;\">11.1. List of Marketed Products in the 7MM<\/p>\n<p style=\"text-align: justify;\">11.2. Drug Name: Company Name<\/p>\n<p style=\"text-align: justify;\">11.2.1. Product Description<\/p>\n<p style=\"text-align: justify;\">11.2.2. Regulatory Milestones<\/p>\n<p style=\"text-align: justify;\">11.2.3. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">11.2.4. Pivotal Clinical Trials<\/p>\n<p style=\"text-align: justify;\">11.2.5. Summary of Pivotal Clinical Trial<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\">12. Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12.1. Key Cross<\/p>\n<p style=\"text-align: justify;\">12.2. Drug Name: Company Name<\/p>\n<p style=\"text-align: justify;\">12.2.1. Product Description<\/p>\n<p style=\"text-align: justify;\">12.2.2. Other Developmental Activities<\/p>\n<p style=\"text-align: justify;\">12.2.3. Clinical Development<\/p>\n<p style=\"text-align: justify;\">12.2.4. Safety and Efficacy<\/p>\n<p style=\"text-align: justify;\">12.2.5. Product Profile<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\">13. Prader-Willi Syndrome: Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">13.1. Key Findings<\/p>\n<p style=\"text-align: justify;\">13.2. Prader-Willi Syndrome Market Size in 7MM<\/p>\n<p style=\"text-align: justify;\">13.3. Prader-Willi Syndrome Market Size by Therapies in the 7MM<\/p>\n<p style=\"text-align: justify;\">14. Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15. 7MM: Market Outlook<\/p>\n<p style=\"text-align: justify;\">15.1. United States: Market Size<\/p>\n<p style=\"text-align: justify;\">15.1.1. Prader-Willi Syndrome Total Market Size in the United States<\/p>\n<p style=\"text-align: justify;\">15.1.2. Prader-Willi Syndrome Market Size by Therapies in the United States<\/p>\n<p style=\"text-align: justify;\">15.2. EU-5 countries: Market Size and Outlook<\/p>\n<p style=\"text-align: justify;\">15.3. Germany Market Size<\/p>\n<p style=\"text-align: justify;\">15.3.1. Prader-Willi Syndrome Total Market Size in Germany<\/p>\n<p style=\"text-align: justify;\">15.3.2. Prader-Willi Syndrome Market Size by Therapies in Germany<\/p>\n<p style=\"text-align: justify;\">15.4. France Market Size<\/p>\n<p style=\"text-align: justify;\">15.4.1. Prader-Willi Syndrome Total Market Size in France<\/p>\n<p style=\"text-align: justify;\">15.4.2. Prader-Willi Syndrome Market Size by Therapies in France<\/p>\n<p style=\"text-align: justify;\">15.5. Italy Market Size<\/p>\n<p style=\"text-align: justify;\">15.5.1. Prader-Willi Syndrome Total Market Size in Italy<\/p>\n<p style=\"text-align: justify;\">15.5.2. Prader-Willi Syndrome Market Size by Therapies in Italy<\/p>\n<p style=\"text-align: justify;\">15.6. Spain Market Size<\/p>\n<p style=\"text-align: justify;\">15.6.1. Prader-Willi Syndrome Total Market Size in Spain<\/p>\n<p style=\"text-align: justify;\">15.6.2. Prader-Willi Syndrome Market Size by Therapies in Spain<\/p>\n<p style=\"text-align: justify;\">15.7. United Kingdom Market Size<\/p>\n<p style=\"text-align: justify;\">15.7.1. Prader-Willi Syndrome Total Market Size in the United Kingdom<\/p>\n<p style=\"text-align: justify;\">15.7.2. Prader-Willi Syndrome Market Size by Therapies in the United Kingdom<\/p>\n<p style=\"text-align: justify;\">15.8. Japan Market Outlook<\/p>\n<p style=\"text-align: justify;\">15.8.1. Japan Market Size<\/p>\n<p style=\"text-align: justify;\">15.8.2. Prader-Willi Syndrome Total Market Size in Japan<\/p>\n<p style=\"text-align: justify;\">15.8.3. Prader-Willi Syndrome Market Size by Therapies in Japan<\/p>\n<p style=\"text-align: justify;\">16. Access and Reimbursement Overview of Prader-Willi Syndrome<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">20.1. Bibliography<\/p>\n<p style=\"text-align: justify;\">20.2. Report Methodology<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\">23. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC:&nbsp;<strong>&nbsp;https:\/\/www.delveinsight.com\/sample-request\/prader-willi-syndrome-market<\/strong><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=praderwilli-syndrome-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/prader-willi-syndrome-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/prader-willi-syndrome-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/prader-willi-syndrome-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=praderwilli-syndrome-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Prader-Willi Syndrome &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221; DelveInsight has launched a new report on &#8220;Prader-Willi Syndrome &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221;. &nbsp; DelveInsight&#8217;s &#8220;Prader-Willi Syndrome &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221;&nbsp;report delivers an in-depth understanding &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/praderwilli-syndrome-market-analysis-market-size-epidemiology-leading-companies-drugs-and-competitive-analysis-by-delveinsight_502239.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-502239","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/502239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=502239"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/502239\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=502239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=502239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=502239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}